CNTX Stock — Context Therapeutics Inc.: Cash, EV, Pipeline

What they do

We are a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies (“bsAb”) for solid tumors. Our goal is to build an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 (“CLDN6”) x CD3 TCE, CT-95, a Mesothelin (“MSLN”) x CD3 TCE, and CT-202, a Nectin cell adhesion protein 4 (“Nectin-4”) x CD3 TCE.

Source: 10-K FY2025 via SEC EDGAR

Share price

$0.19

Market cap

$17.8M

Cash

$43.0M

Enterprise value

-$25.2M

Balance sheet

Cash	$43.0M
Debt	$0.0M
Net cash	$43.0M
Enterprise value	-$25.2M
Basic shares	91.9M shares
Fully diluted shares	109.7M shares
Fully diluted market cap	$20.8M
Cash per share	$0.47
Quarterly burn	$7.0M
Cash runway	6.1 quarters

Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.

Share structure

Common

91.9M

Pre-funded warrants

3.3M

Options

8.6M

RSUs

0.0M

Warrants

5.9M

Converts

0.0M

Conv preferred

0.0M

ESPP reserve

—

FDSO

109.7M

Cap table as of 2026-06-30.

Price history

Loading CNTX daily closes…

Loading price history…

Next catalyst

CT-95 · Jan 12 - Feb 23 in 9 wks · Phase 1 · Mesothelin-Expressing Tumors; Epithelial Ovarian Cancer; Malignant Pleural Mesothelioma, Advanced

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Jan 12 - Feb 23 in 9 wks	CT-95	Phase 1	Mesothelin-Expressing Tumors; Epithelial Ovarian Cancer; Malignant Pleural Mesothelioma, Advanced	—
Jul 12 - Aug 23 in 20 mo	CTIM-76	Phase 1	Platinum-resistant Ovarian Cancer; Testicular Cancer; Endometrial Cancer	—
Feb 12 - Mar 26 in 40 mo	CT-202	Phase 1	Triple Negative Breast Cancer (TNBC); Colorectal Cancer; Urothelial Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

CTIM-76

Phase 1 · Active Modality: bispecific antibody (T cell engager)

Target Claudin 6 (CLDN6) x CD3

Partnerships Integral Molecular: collaboration and licensing agreement for CLDN6 bispecific antibodies (amended Feb 2024; up to $15M development/regulatory milestones, up to $12.5M sales milestones, flat 6% royalty on net sales no sooner than Feb 1, 2034); Lonza: non-exclusive manufacturing license (royalties up to low single digits plus annual payments up to <$500K per asset)

Indications

CLDN6-positive gynecologic and testicular cancers (Phase 1)
Platinum-resistant ovarian cancer (Phase 1)

Catalysts

— second quarter of 2027
— first quarter of 2027

Status note First patient dosed January 2025; interim Phase 1a data presented June 2026. FDA granted Fast Track designation April 2, 2026 for platinum-resistant ovarian cancer in patients who received all standard of care therapies.

CT-202

Phase 1 · Active Modality: bispecific antibody (T cell engager)

Aliases formerly BA3362

Target Nectin-4 x CD3

Partnerships BioAtla: exclusive worldwide license to BioAtla Assets incl. BA3362 ($11M upfront; May 2026 amendment: $4.5M + $2M paid, license now irrevocable, royalty-free, fully paid-up; no future milestones or royalties owed); Lonza: non-exclusive manufacturing license (royalties up to low single digits plus annual payments up to <$500K per asset)

Indications

Nectin-4-positive urothelial, colorectal, and triple-negative breast cancers (Phase 1)

Catalysts

— third quarter of 2026
— second half of 2027

Status note First-in-human Phase 1 cleared in Australia (April 2026 HREC approval/CTN acknowledgement); first patient expected dosed Q3 2026.

CT-95

Phase 1 · Terminated Modality: bispecific antibody (T cell engager)

Target Mesothelin (MSLN) x CD3

Partnerships Link: asset purchase of CT-95-related patent rights, know-how, regulatory filings and drug inventory

Indications

MSLN-positive solid tumors (high grade serous ovarian, pancreatic, mesothelioma) (Phase 1)

Status note Internal development discontinued August 5, 2026 under portfolio prioritization and capital allocation strategy; Phase 1 trial (first patient dosed April 2025) being wound down.

Per-asset detail extracted from the 10-Q filed 2026-08-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	CT-95
Lead indication	Mesothelin-Expressing Tumors
Lead phase	Phase 1
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT06756035	Phase 1	Recruiting	Sponsor	CNTX	—	Mesothelin-Expressing Tumors; Epithelial Ovarian Cancer; Malignant Pleural Mesothelioma, Advanced	—
NCT06515613	Phase 1	Recruiting	Sponsor	CNTX	—	Platinum-resistant Ovarian Cancer; Testicular Cancer; Endometrial Cancer	—
NCT07545122	Phase 1	Recruiting	Sponsor	CNTX	—	Triple Negative Breast Cancer (TNBC); Colorectal Cancer; Urothelial Cancer	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Context Therapeutics Inc. on ClinicalTrials.gov

Specialist fund holders

Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	750,969	+399,875	0.02%	2026-08-14
Cormorant Asset Management	0	-529,550	0.00%	2026-08-14
Great Point Partners	0	-2,238,496	0.00%	2026-08-14

Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

Latest news

Loading headlines…

Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.

CNTX — Context Therapeutics Inc. ☆

What they do

Balance sheet

Share structure

Price history

Next catalyst

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Specialist fund holders

Latest news

CNTX — Context Therapeutics Inc.